Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

NCT02198482 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.

NCT NCT02198482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02198482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Lead sponsor
University of Ulm
Phase
Phase 2
Overall status
Terminated
Start date
February 29, 2016
Completion date
November 30, 2016
Enrollment
6 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia (aml), high-risk myelodysplastic syndrome (mds)